The Greater Cannabis Company, Inc. (GCAN)

Get Top Rated Stock Alerts Active Traders Depend On

Sign Up Today For FREE News Driven Alerts

GREATER CANNABIS COMPANY LICENSES CBD PATCH TECHNOLOGY TO MAJOR BRAZILIAN RETAIL PHARMACY COMPANY

Baltimore, MD – April 15, 2019 – The Greater Cannabis Company (OTCQB: GCAN), a market leader and innovator in the development and commercialization of cannabinoid delivery systems, today announced it has entered into a letter of agreement (LOI) with a major Brazilian retail pharmacy company, CBR Participacoes SA, to market Greater Cannabis Company’s eluting patch technology for cannabis in Brazil.

 

As part of the agreement, CBR Participacoes will distribute the technology to its network of 300 pharmacies and more than 1,500 point-of-sale retailers in the country, serving the Brazil’s growing demand and market for cannabis products. The agreement is effectively immediately through 2021.

 

“We continue to see explosive interest and growth for our technology in Brazil as the country’s cannabis market continues to expand at an exponential rate,” said Aitan Zacharin, Chief Executive Officer of Greater Cannabis Company. “Our new licensing agreement with CBR Participacoes taps into this and will represent the first of many additional agreements we are currently pursuing,” concluded Mr. Zacharin.

 

Cannabidiol (CBD) has been legalized for therapeutic use since 2015 in Brazil, the largest country in both South America and Latin America. The country began allowing import of CBD oil in products that have potential medical benefit later that year and has continued to advance its legislation and legalization of cannabis to date. Greater Cannabis Company’s eluting patch technology meets a global demand for alternative methods of cannabis administration and has demonstrated stability and bioavailability across a broad range of lab studies conducted by the Company. The Company believes it is poised for significant market growth and traction in Brazil as its government is increasingly approving the use of CBD and cannabis products by its citizens.

 

“After a thorough and diligent search and testing process, we found that Greater Cannabis Company would be the ideal partner for us due to its combined technology, knowledge and expertise in cannabis business and products,” said Rogerio P. Rabello, Chief Executive Officer of CBR Participacoes SA. “Although there are many innovative and promising solutions in the market, we believe GCANRx’s technological advantages are far advanced and will prove to be critical to ensuring the success of a mutually beneficial and long-term relationship,” concluded Mr. Rabello.

 

GCANRx Continues Expanding Across Brazil’s Large and Growing CBD Market

 

Today’s announcement demonstrates The Greater Cannabis Company’s continued traction and expansion in Brazil.  Last week, the Company announced an agreement with leading Brazilian beauty and personal care company Allume Cosmeticos to empower Allume to market and distribute CBD-infused beauty and personal care to its retail partners, distributors and millions of customers across Brazil.

For additional information about The Greater Cannabis Company, please visit www.gcanrx.com.

 

About The Greater Cannabis Company

 

The Greater Cannabis Company (OTCQB: GCAN) is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid delivery systems. Greater Cannabis deploys its patented technology platform for use in the cannabis industry. The Company’s conveyance platform can be utilized to deliver cannabinoids without the harmful side effects found with other routes of cannabinoid administration. The technology is versatile in that for the first-time patients can receive lower dosing, enhanced bioavailability, and controlled rapid and delayed release using a fully dissolvable, non-irritant oral eluting patch. Greater Cannabis’ mission is to bring our technology to the global market through partnerships with leading cannabis and pharmaceutical companies, for the benefit of patients and consumers. More information on the Greater Cannabis Company and its technology can be found on the Company’s website, www.gcanrx.com.

 

Disclaimer: GCANRx relies upon the Safe Harbor Laws of 1933, 1934 and 1995 for all public news releases. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the company’s best judgment based upon current information and involve several risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the company include, but are not limited to, government regulation; managing and maintaining growth; the effect of adverse publicity; litigation; competition; and other factors which may be identified from time to time in the company’s public announcements.

 

 

Source:  The Greater Cannabis Company

 

Greater Cannabis Company Partners with Allume Cosmeticos To Develop New Cosmetics Line Press Release |

Agreement with Leading Beauty And Personal Care Brand In Brazil Represents Company’s First Contract in Emerging CBD Cosmetics and Beauty Market

 

Baltimore, MD – April 11, 2019 Greater Cannabis Company (OTCQB: GCAN), a market leader and innovator in the development and commercialization of cannabinoid delivery systems, today announced a letter of agreement (LOI) with leading Brazilian beauty and personal care company Allume Cosmeticos. Under the terms of the agreement, Greater Cannabis Company will customize formulations and incorporate its proprietary technology to infuse pharmaceutical-grade cannabidiol (CBD) into Allume’s new line of CBD-based cosmetic products, empowering Allume to market and distribute CBD-infused beauty and personal care for its retail partners, distributors and millions of customers.

CBD has shown multiple beauty and personal care benefits, ranging from antioxidants for anti-aging to anti-inflammatory for acne and other treatments. Its effectiveness in these applications requires excellent  product bioavailability and reliable stability. Greater Cannabis Company’s patented technology platform has demonstrated this in the delivery of cannabis actives across different mediums in lab studies, including beauty and personal care. The company combines this with expertise and innovation in concept development to full-scale commercialization to assist its retail and manufacturing clients in bringing CBD products to market.

“The Brazilian cosmetics market, the fifth largest in the world, has long been a global leader in beauty and personal care products, with Allume on the forefront of product concept and innovation for over 40 years,” said Aitan Zacharin, Chief Executive Officer of Greater Cannabis Company. “We are honored to have been selected by Allume Cosmeticos to develop its CBD products, which we believe is a testament of the strength and efficacy of our proprietary CBD formulation technology and the industry’s increasing demand for it..”

Today’s announcement of its relationship with Allume Cosmeticos continues The Greater Cannabis Company’s growth and position as a leading innovator in the global CBD industry, and is just one of many dynamic partnership and customer announcements it will share in the coming year. For additional information about The Greater Cannabis Company, please visit www.gcanrx.com.

About The Greater Cannabis Company:

The Greater Cannabis (OTCQB: GCAN) is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid delivery systems. Greater Cannabis deploys its patented technology platform for use in the cannabis industry. The Company’s conveyance platform can be utilized to deliver cannabinoids without the harmful side effects found with other routes of cannabinoid administration. The delivery system is versatile in that consumers and patients can receive lower dosing, enhanced bioavailability, and controlled rapid and delayed release. Greater Cannabis’ mission is to bring its technology to the global market through partnerships with leading cannabis, consumer products, and pharmaceutical companies, for the benefit of patients and consumers. More information on the Greater Cannabis Company and its technology can be found on the Company’s website, www.gcanrx.com.

Disclaimer: GCANRx relies upon the Safe Harbor Laws of 1933, 1934 and 1995 for all public news releases. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the company’s best judgment based upon current information and involve several risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the company include, but are not limited to, government regulation; managing and maintaining growth; the effect of adverse publicity; litigation; competition; and other factors which may be identified from time to time in the company’s public announcements.

###

Contact:
The Greater Cannabis Company, Inc.
443-738-4051
info@gcanrx.com
www.gcanrx.com

About The Greater Cannabis Company


 

GCANRx is a publicly traded biotechnology company led by an experienced team of executives and scientists. The company is focused on the the development and commercialization of innovative Cannabinoid delivery systems.

 

GCANRx has leveraged its licensed, patented technology platform, which has been successfully applied for drug delivery in other fields of use, for cannabis patients and consumers. GCANRx’s conveyance platform can be utilized to deliver cannabis actives without requiring smoking, vaporizing, or other forms of administration.

 

The technology is versatile in that for the first time patients can receive personalized dosing, higher bioavailability, and a controlled rapid and/or slow release using just one, unobtrusive eluting oral patch. GCANRx’s mission is to bring this technology to the global market through partnerships with leading cannabis and pharmaceutical companies, for the benefit of patients and consumers.

 

 

Adding a New Layer to Cannabis Innovation

 

We are driven to improve lives by leading the industry forward in developing innovative delivery system for the worldwide cannabis market.

 

Market Driven Application

 

Very little has changed in how Cannabis is delivered. Patients, providers, and consumers are showing a rising demand for safer routes of administration, while achieving proper potency and higher bioavailability. In response to the current deficiencies in the marketplace, GCANRx has developed a product that addresses these unmet needs.

 

Novel Technology

 

Our biotechnology stems from over a decade of research and development, and has been used in pharmaceutical applications by some of the World’s largest pharmaceutical companies.

 

Cannabis Delivery of the Future

 

GCANRx is setting the bar for improved onset of action, dosing accuracy, enhanced efficacy, and safety in the delivery of cannabinoids.

 

GCANRx has the exclusive worldwide license for PharMedica’s Eluting Transmucosal Patch Platform (ETP) for non-invasive drug delivery in the Cannabis field.

 

The company holds the rights to new delivery technologies using a bio-adhesive, adjustable dose, and fully dissolvable, non-irritant patch, which provides for a needle free, intra-oral systemic drug delivery. The conveyance technology is designed to accelerate and enhance the delivery and bioavailability of medicines and cannabis actives when compared to traditional methods of enteral administration.

 

Lower Dosing

 

The transmembrane functionality enables needle-free, transmucosal drug delivery, administering the medicine directly into the blood system while bypassing the digestive and hepatic systems, thereby increasing the bioavailability and lowering the dose required to achieve desired therapeutic effects.

 

Multi-Dosing

 

The mucoadhesive film is applied on the internal mouth, and is made of multiple dosage form layers, enabling loading of different dosages on the same thin film patch.

 

Controlled Release

 

Two or more layers of the Eluting Patch offers diverse timing of drug administration. The inner film layer is attached to the membrane providing fast release, followed by the outer film layers providing a slow and sustained release.

 

Versatility

 

Each layer contains similar or different drugs, depending of the purpose of the medical treatment.

 

Source:  https://www.gcanrx.com/

Disclaimer

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated twenty five hundred dollars for The Greater Cannabis Company, Inc. current news coverage by a non-affiliated third party.  FNMG HOLDS NO SHARES OF The Greater Cannabis Company, Inc.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Sign Up & Get FREE News Alerts From FNM Today!